ABBV · News · 20261102N

SKYRIZI Crohn’s Disease Progress

AbbVie Inc. · 2026-11-02 · Importance 59 · Surprise 82

AbbVie’s experimental ABBV-466, a combination of SKYRIZI and trosunilimab, showed positive Phase 2 results in Crohn’s disease. The combination nearly doubled the remission rate achieved by SKYRIZI alone, according to the report. It targets multiple inflammation pathways and could offer a more effective treatment option in inflammatory bowel disease, although Phase 3 trials remain ahead.

Key facts

• AbbVie’s experimental combination ABBV-466, consisting of Skyrizi and trosunilimab, showed a Phase 2 Crohn’s disease remission rate nearly double that of Skyrizi alone; Phase 3 trials are still ahead. source